Literature DB >> 30829831

Validation of an Algorithm for Claims-based Incidence of Prostate Cancer.

Lauren E Parlett1, Daniel C Beachler2, Stephan Lanes2, Robert N Hoover3, Michael B Cook3.   

Abstract

BACKGROUND: Prostate cancer is a commonly studied outcome in administrative claims studies, but there is a dearth of validated case identifying algorithms. The long-term development of the disease increases the difficulty in separating prevalent from incident prostate cancer. The purpose of this validation study was to assess the accuracy of a claims algorithm to identify incident prostate cancer among men in commercial and Medicare Advantage US health plans.
METHODS: We identified prostate cancer in claims as a prostate cancer diagnosis within 28 days after a prostate biopsy and compared case ascertainment in the claims with the gold standard results from the Georgia Comprehensive Cancer Registry (GCCR).
RESULTS: We identified 74,008 men from a large health plan claims database for possible linkage with GCCR. Among the 382 prostate cancer cases identified in claims, 312 were also identified in the GCCR (positive predictive value [PPV] = 82%). Of the registry cases, 91% (95% confidence interval = 88, 94) were correctly identified in claims. Claims and registry diagnosis dates of prostate cancer matched exactly in 254/312 (81%) cases. Nearly half of the false-positive cases also had claims for prostate cancer treatment. Thirteen (43%) false-negative cases were classified as noncases by virtue of having a biopsy and diagnosis >28 days apart as required by the algorithm. Compared to matches, false-negative cases were older men with less aggressive prostate cancer.
CONCLUSIONS: Our algorithm demonstrated a PPV of 82% with 92% sensitivity in ascertaining incident PC. Administrative health plan claims can be a valuable and accurate source to identify incident prostate cancer cases.

Entities:  

Mesh:

Year:  2019        PMID: 30829831      PMCID: PMC6456424          DOI: 10.1097/EDE.0000000000001007

Source DB:  PubMed          Journal:  Epidemiology        ISSN: 1044-3983            Impact factor:   4.822


  17 in total

Review 1.  Identifying health outcomes in healthcare databases.

Authors:  Stephan Lanes; Jeffrey S Brown; Kevin Haynes; Michael F Pollack; Alexander M Walker
Journal:  Pharmacoepidemiol Drug Saf       Date:  2015-08-18       Impact factor: 2.890

2.  Ability of Medicare claims data and cancer registries to identify cancer cases and treatment.

Authors:  D K McClish; L Penberthy; M Whittemore; C Newschaffer; D Woolard; C E Desch; S Retchin
Journal:  Am J Epidemiol       Date:  1997-02-01       Impact factor: 4.897

Review 3.  The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA.

Authors:  Katherine Fleshner; Sigrid V Carlsson; Monique J Roobol
Journal:  Nat Rev Urol       Date:  2016-12-20       Impact factor: 14.432

4.  Insurance Transitions and Changes in Physician and Emergency Department Utilization: An Observational Study.

Authors:  Michael L Barnett; Zirui Song; Sherri Rose; Asaf Bitton; Michael E Chernew; Bruce E Landon
Journal:  J Gen Intern Med       Date:  2017-05-18       Impact factor: 5.128

5.  Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort.

Authors:  C J Newschaffer; K Otani; M K McDonald; L T Penberthy
Journal:  J Natl Cancer Inst       Date:  2000-04-19       Impact factor: 13.506

6.  Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer.

Authors:  Matthew R Smith; Won Chan Lee; Jane Brandman; Qin Wang; Marc Botteman; Chris L Pashos
Journal:  J Clin Oncol       Date:  2005-11-01       Impact factor: 44.544

7.  Patient opinions on prostate cancer screening are swayed by the United States Preventative Services Task Force recommendations.

Authors:  Matthew J Maurice; Robert Abouassaly
Journal:  Urology       Date:  2014-06-12       Impact factor: 2.649

8.  A retrospective analysis illustrating the substantial clinical and economic burden of prostate cancer.

Authors:  E D Crawford; L Black; M Eaddy; E J Kruep
Journal:  Prostate Cancer Prostatic Dis       Date:  2010-02-02       Impact factor: 5.554

9.  Real-World Corticosteroid Utilization Patterns in Patients with Metastatic Castration-Resistant Prostate Cancer in 2 Large US Administrative Claims Databases.

Authors:  Marie-Hélène Lafeuille; Jonathan Gravel; Amanda Grittner; Patrick Lefebvre; Lorie Ellis; R Scott McKenzie
Journal:  Am Health Drug Benefits       Date:  2013-07

10.  Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends.

Authors:  Ruth Etzioni; David F Penson; Julie M Legler; Dante di Tommaso; Rob Boer; Peter H Gann; Eric J Feuer
Journal:  J Natl Cancer Inst       Date:  2002-07-03       Impact factor: 13.506

View more
  4 in total

1.  Testosterone Therapy in Relation to Prostate Cancer in a U.S. Commercial Insurance Claims Database.

Authors:  Michael B Cook; Daniel C Beachler; Lauren E Parlett; Philip T Cochetti; William D Finkle; Stephan Lanes; Robert N Hoover
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-10-22       Impact factor: 4.254

2.  Algorithm to Identify Incident Epithelial Ovarian Cancer Cases Using Claims Data.

Authors:  Sarah P Huepenbecker; Hui Zhao; Charlotte C Sun; Shuangshuang Fu; Weiguo He; Sharon H Giordano; Larissa A Meyer
Journal:  JCO Clin Cancer Inform       Date:  2022-03

3.  Validation of Self-reported Cancer Diagnoses Using Medicare Diagnostic Claims in the US Health and Retirement Study, 2000-2016.

Authors:  Megan A Mullins; Jasdeep S Kler; Marisa R Eastman; Mohammed Kabeto; Lauren P Wallner; Lindsay C Kobayashi
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-11-04       Impact factor: 4.090

4.  Identification of cancer patients using claims data from health insurance systems: A real-world comparative study.

Authors:  Hongrui Tian; Ruiping Xu; Fenglei Li; Chuanhai Guo; Lixin Zhang; Zhen Liu; Mengfei Liu; Yaqi Pan; Zhonghu He; Yang Ke
Journal:  Chin J Cancer Res       Date:  2019-08       Impact factor: 5.087

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.